News

The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

The LIGHTHOUSE study a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial is currently investigating the safety and tolerability of ASTN-201 for XLRS.

Researchers noted that patients with sickle cell disease had an increased risk of developing any retinal vascular occlusion.

Tim Cherry, PhD, and Debarshi Mustafi, MD, PhD, have been awarded a $150,000 Clinical & Research Synergy Pilot Award from Seattle Children’s Research Institute to determine the genetic causes of unsolved inherited retinal diseases.

The authors explained that estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

Researchers conducted a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated rhegmatogenous retinal detachment at the Wilmer Eye Institute from January 2008 to December 2018.

Researchers from the Shanghai Jiao Tong University School of Medicine developed a deep learning–based model for early identification of myopia, strabismus, and ptosis using 1419 facial photographs from 476 individuals.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

The SOL-R clinical trial of is deemed appropriate for use as Ocular Therapeutix’s second adequate and well controlled study of axitinib intravitreal implant.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

LUBT010 is a ranibizumab biosimilar to Lucentis that achieved its primary endpoint in this study.

This clinical milestone marks a new step in treating the condition with a potential long-term benefit.

Investigators at Shandong Normal University in China discovered that ciliary disassembly in photoreceptors is a significant event in the pathogenesis of retinal degeneration.

According to the company, additional data from its Phase 2 ARCHER trial showed both vision protection in standard and low light conditions, and structural protection in regions of the eye key for visual acuity.

Stephanie Marioneaux, MD, gives insight into the inspiration and research discussed in her talk “First in Medicine: An African American perspective from 1700 to 1940" as the Patricia Bath Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

The service expands ophthalmological capabilities and enables providers to deliver the gift of sight to patients with complex retinal conditions in Harlem.

Researchers at National Taiwan University Hospital concluded that significant differences were observed in visual acuity, refractive state and myopia rate between patients with inherited retinal disease and the general population.

M. Roy Wilson, MD, touches upon reconceptualizing the use of race in medicine as part of his Robert Copeland Distinguished Lecture at the National Medical Association's annual conference in New York City, NY.

Kathryn Colby, MD, PhD, described diagnosing and managing these tumors at the National Medical Association annual meeting, Ophthalmology Session in New York.

Fasika Woreta, MD, discussed the Roman-Barnes lecture and the cornea care landscape ahead of the National Medical Association meeting.

Ore-ofe O. Adesina, MD, described the advances in diagnostics and therapeutics in Neuro-Ophthalmology at the National Medical Association annual meeting.

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.